Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Reference96 articles.
1. Incidence and survival trends in mantle cell lymphoma;Epperla;Br J Haematol,2018
2. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies;Advani;J Clin Oncol,2013
3. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes;Dubovsky;Blood,2013
4. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy;Honigberg;Proc Natl Acad Sci U S A,2010
5. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma;Wang;N Engl J Med,2013
Cited by 17 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The preclinical discovery and development of orelabrutinib as a novel treatment option for B-cell lymphoid malignancies;Expert Opinion on Drug Discovery;2023-07-13
2. Determination of Orelabrutinib in Human Plasma Using LC-MS/MS;Therapeutic Drug Monitoring;2023-05-05
3. Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression;The Journal of Immunology;2022-11-15
4. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies;Journal of Hematology & Oncology;2022-10-01
5. Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis;DARU Journal of Pharmaceutical Sciences;2022-09-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3